Diabetes drug trial aims to boost success of heart ablation
NCT ID NCT07331727
Summary
This study is testing whether adding the drug dapagliflozin around the time of a heart ablation procedure can help prevent the irregular heartbeat from coming back. It will involve 280 adults with a specific type of long-lasting atrial fibrillation who have extra fat around the heart. The goal is to see if this drug, given for a short time, can improve the long-term success of the ablation by reducing inflammation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Chest Hospital
Shanghai, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.